Imugene has agreed to acquire a worldwide exclusive licence for a highly potent, chimeric oncolytic poxvirus known as CF33. The company proposes to progress CF33 into a Phase I safety study in 2020, including a cohort treated with CF33 in combination with a checkpoint inhibitor. This strategy is similar to that pursued by Viralytics, which was acquired by Merck for A$502m in 2018 after conducting studies of its Cavatak oncolytic virus in combination with Merck’s checkpoint inhibitor, Ke
15 Jul 2019
Imugene - In-licensing deal for CF33 oncolytic virus
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Imugene - In-licensing deal for CF33 oncolytic virus
Imugene Ltd (IMU:ASX) | 0 0 -4.6% | Mkt Cap: 60.0m
- Published:
15 Jul 2019 -
Author:
Dr Dennis Hulme -
Pages:
13
Imugene has agreed to acquire a worldwide exclusive licence for a highly potent, chimeric oncolytic poxvirus known as CF33. The company proposes to progress CF33 into a Phase I safety study in 2020, including a cohort treated with CF33 in combination with a checkpoint inhibitor. This strategy is similar to that pursued by Viralytics, which was acquired by Merck for A$502m in 2018 after conducting studies of its Cavatak oncolytic virus in combination with Merck’s checkpoint inhibitor, Ke